Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Net Cash Flow (2016 - 2025)

IGC Pharma (IGC) has disclosed Net Cash Flow for 16 consecutive years, with $646000.0 as the latest value for Q3 2025.

  • Quarterly Net Cash Flow rose 341.95% to $646000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$473000.0 through Sep 2025, up 67.91% year-over-year, with the annual reading at -$786000.0 for FY2025, 60.54% up from the prior year.
  • Net Cash Flow for Q3 2025 was $646000.0 at IGC Pharma, up from $24000.0 in the prior quarter.
  • The five-year high for Net Cash Flow was $13.6 million in Q1 2021, with the low at -$2.5 million in Q4 2021.
  • Average Net Cash Flow over 5 years is $12052.6, with a median of -$1.1 million recorded in 2024.
  • Peak annual rise in Net Cash Flow hit 583.14% in 2021, while the deepest fall reached 1194.24% in 2021.
  • Over 5 years, Net Cash Flow stood at -$2.5 million in 2021, then soared by 32.65% to -$1.7 million in 2022, then rose by 0.96% to -$1.6 million in 2023, then soared by 34.75% to -$1.1 million in 2024, then surged by 160.04% to $646000.0 in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $646000.0, $24000.0, and -$67000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.